Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b study of CP101 in chronic hepatitis B patients

Next Previous
Trial Profile

A Phase 1b study of CP101 in chronic hepatitis B patients

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 Mar 2022 Status changed from planning to suspended, according to a Finch Therapeutics Group media release.
  • 31 Mar 2022 According to a Finch Therapeutics Group media release, company has paused development of CP101 for the treatment of chronic HBV following a strategic review of the pipeline.
  • 10 Aug 2021 According to a Finch Therapeutics Group media release, trial is planed to initiate in early 2022, with an initial safety readout in the first half of 2022 and topline data from multiple cohorts available in the second half of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top